Shares Outstanding (Quarterly) Chart

View Shares Outstanding (Quarterly) for ONC.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shares Outstanding (Quarterly) Chart
Start Trial

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 104.17M
March 31, 2026 102.26M
December 31, 2025 102.00M
September 30, 2025 101.77M
June 30, 2025 101.01M
March 31, 2025 97.25M
December 31, 2024 97.63M
September 30, 2024 97.25M
June 30, 2024 98.63M
March 31, 2024 95.58M
December 31, 2023 95.36M
September 30, 2023 97.01M
June 30, 2023 96.64M
March 31, 2023 95.61M
December 31, 2022 95.11M
September 30, 2022 94.85M
June 30, 2022 94.54M
March 31, 2022 102.68M
December 31, 2021 102.68M
September 30, 2021 93.33M
June 30, 2021 92.66M
March 31, 2021 92.10M
Date Value
December 31, 2020 91.60M
September 30, 2020 90.99M
June 30, 2020 78.08M
March 31, 2020 77.54M
December 31, 2019 61.64M
September 30, 2019 60.34M
June 30, 2019 60.34M
March 31, 2019 59.80M
December 31, 2018 59.71M
September 30, 2018 59.71M
June 30, 2018 59.71M
March 31, 2018 59.71M
December 31, 2017 59.71M
September 30, 2017 59.71M
June 30, 2017 59.71M
March 31, 2017 59.71M
December 31, 2016 59.71M
September 30, 2016 59.71M
June 30, 2016 59.71M
March 31, 2016 59.71M
December 31, 2015 59.31M
September 30, 2015 59.31M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Basilea Pharmaceutica AG --
Santhera Pharmaceuticals Holding AG --
AC Immune SA 91.10M
CRISPR Therapeutics AG 96.66M
Idorsia Ltd. 263.06M